News on Hepatitis continually updated from thousands of sources around the net.
1 hr ago | The Jersey Journal
Slick Aguilar, lead guitarist of Jefferson Starship, has a liver transplant last year and has run up over $1 million in medical bills.
Trending on the Topix Network
5 hrs ago | Newswise
March 11, 2014 - Patrizia Cazzaniga had heard the horror stories about early treatments for hepatitis C - multiple daily pills and weekly shots for up to a year, side effects that could be debilitating, and a cure rate of only about 40 percent.
8 hrs ago | Seattle Post-Intelligencer
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences Inc. A panel of California medical experts voted Monday that Gilead's Sovaldi represents a "low value" ... (more)
12 hrs ago | KJRH
Wind Advisory issued March 10 at 3:52PM CDT expiring March 12 at 4:00AM CDT in effect for: Craig, Creek, McIntosh, Mayes, Muskogee, Nowata, Okfuskee, Okmulgee, Osage, Ottawa, Pawnee, Rogers, Tulsa, Wagoner, Washington Fire Weather Warning issued March 11 at 4:57AM CDT expiring March 11 at 10:00PM CDT in effect for: Craig, Creek, Nowata, Okfuskee, ... (more)
13 hrs ago | HIV and Hepatitis
An all-oral regimen of daclatasvir plus simeprevir, without interferon or ribavirin, led to sustained response in 85% to 95% of patients with hepatitis C genotype 1b, but this combination did not work well against genotype 1a, researchers reported last week at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.
PrEP researchers Walid Heneine, Gerardo Garcia-Lerma, Peter Anton, and Craig Hendrix during a 2011 CROI panel HIV researchers from across the globe came together in Boston last week from March 3-6 for the annual Conference on Retroviruses and Opportunistic Infections .
A: Many things can be done to help ensure a traveler's health and safety. See your healthcare provider well before your planned departure date.
Variable responses to the Hepatitis B Virus vaccine have recently been reported as strongly dependent on genetic causes.
A new combination of drugs offers a cure for hepatitis C, the virus that often leads to liver disease.
This easily beats the S&P's return of 1.5% over the same time period. However, can Merck keep the bull run going? Merck released details this week of a phase 2 trial involving a combination of Merck's MK-5172 and MK-8742 to treat patients co-infected with HIV and hepatitis C. The administration of the combination for 12 weeks resulted in robust ... (more)
Physical inactivit... )--GreenHunter Resources, Inc. , announced today that it has declared a monthly cash dividend on the Company's 10.... )--Research and Markets has announced the addition of the "Global Unsaturated Polyester Resin --BRTRC Federal Solutions, a leading mid-sized firm focused on providing integrated technical solutions to the ... (more)
After years of running Minnesota's largest needle exchange, Brian Warden is beginning to see something new among the increasing numbers of suburban and rural heroin users coming to trade in used needles.
Martin Khor, executive director of the South Centre, warns that negotiations on the Trans Pacific Partnership Agreement are a matter of life and death.
Conatus Pharmaceuticals Inc. has announced the initiation of a Phase 2 clinical trial of its lead drug emricasan for the treatment of patients with chronic liver disease and acute exacerbations of chronic liver disease, including acute-on-chronic liver failure, chronic liver failure, Non-alcoholic fatty liver disease and non-alcoholic ... (more)
Promising preliminary results from a trial of Merck's MK-5172 and MK-8742, given with or without ribavirin, showed that the combination therapy was as safe in treating genotype 1 of hepatitis C virus among those coinfected with HIV as it was among those monoinfected with hep C. The treatment appears to boast near-perfect success rates.